11/15/2013

A prospectus offering has brought in $1.1 million for Verisante Technology. The Canadian firm will use part of the proceeds to support its efforts to market, further develop, manufacture and obtain U.S. regulatory approval for its Aura system, which is used to detect skin cancer.

Related Summaries